YC
AXSM icon

Yarbrough Capital’s Axsome Therapeutics AXSM Stock Holding History

Yarbrough Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-842
Closed -$206K – 82
2026
Q2 		$206K Buy
+842
New +$183K 0.01% 87
2026
Q1 		– Sell
-5,054
Closed -$923K – 95
2025
Q4 		$923K Hold
5,054
– – 0.03% 91
2025
Q3 		$614K Hold
5,054
– – 0.02% 112
2025
Q2 		$528K Hold
5,054
– – 0.02% 125
2025
Q1 		$589K Hold
5,054
– – 0.03% 125
2024
Q4 		$428K Hold
5,054
– – 0.02% 137
2024
Q3 		$454K Hold
5,054
– – 0.02% 142
2024
Q2 		$407K Hold
5,054
– – 0.02% 145
2024
Q1 		$403K Buy
+5,054
New +$424K 0.02% 152

Other funds holding AXSM

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return

Yarbrough Capital's AXSM Position: Q3 2026 in Review

Yarbrough Capital sold out of Axsome Therapeutics (AXSM) in Q3 2026, closing a stake of 842 shares — an estimated $206K sold.

Yarbrough Capital first reported a position in AXSM in Q1 2024 and held it in 9 quarters. The position peaked at $923K in Q4 2025. 208 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Yarbrough Capital reported no remaining Axsome Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Yarbrough Capital sold 842 Axsome Therapeutics shares in Q3 2026, an estimated $206K.
  • Yarbrough Capital first reported a position in Axsome Therapeutics in Q1 2024 and held it in 9 quarters.
  • Yarbrough Capital's Axsome Therapeutics position peaked at $923K in Q4 2025.
  • 208 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Yarbrough Capital's 13F filing for Q3 2026, filed 19 Oct 2026.